FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2133068052> ?p ?o ?g. }

• W2133068052 endingPage "1981" @default.
• W2133068052 startingPage "1974" @default.
• W2133068052 abstract "Purpose To identify predictors of ocular surface squamous neoplasm (OSSN) recurrence after operative resection. Design Retrospective case series. Participants Three hundred eighty-nine consecutive patients who underwent excisional biopsy for OSSN lesions at the Bascom Palmer Eye Institute from January 1, 2001, to September 20, 2010. Methods Review of pathology records and patient charts. Main Outcome Measures Identification of factors predictive of OSSN recurrence. Results Of 389 excised OSSN lesions, 44 recurred during follow-up. The 1-year recurrence rate was 10% and the 5-year recurrence rate was 21%, with a mean time to recurrence in those with a recurrence of 2.5 years (standard deviation, 3.4). Using the American Joint Committee on Cancer (AJCC) clinical staging system, T3 and T2 lesions portended a higher risk of recurrence compared with T1 (T2/T1 hazard ratio [HR], 2.05 [P = 0.04]; T3/T1 HR, 2.31 [P = 0.07]). In addition, a location characteristic that increased the risk of tumor recurrence was tarsal involvement (AJCC T3 stage lesion; HR, 4.12; P = 0.007). Nasal location was associated with a decreased risk of tumor recurrence (HR, 0.41; P = 0.008). Pathologic characteristics significantly associated with tumor recurrence were the presence of positive margins (HR, 2.73; P = 0.008) and higher grade lesions (carcinoma in situ and squamous cell carcinoma versus dysplasia; HR, 2.55; P = 0.02). Treatment with adjuvant cryotherapy significantly decreased the risk of tumor recurrence (HR, 0.51; P = 0.03). In those patients with positive margins, the use of postoperative topical interferon therapy lowered the recurrence rate to a level similar to that of patients with negative margins. Conclusions Certain patient and tumor factors are associated with a higher risk of OSSN recurrence after operative excision, such as tarsal tumor location and positive surgical margins. Postoperative adjuvant therapy should be considered in patients with high-risk OSSN characteristics. Financial Disclosure(s) The authors have no proprietary or commercial interest in any materials discussed in this article. To identify predictors of ocular surface squamous neoplasm (OSSN) recurrence after operative resection. Retrospective case series. Three hundred eighty-nine consecutive patients who underwent excisional biopsy for OSSN lesions at the Bascom Palmer Eye Institute from January 1, 2001, to September 20, 2010. Review of pathology records and patient charts. Identification of factors predictive of OSSN recurrence. Of 389 excised OSSN lesions, 44 recurred during follow-up. The 1-year recurrence rate was 10% and the 5-year recurrence rate was 21%, with a mean time to recurrence in those with a recurrence of 2.5 years (standard deviation, 3.4). Using the American Joint Committee on Cancer (AJCC) clinical staging system, T3 and T2 lesions portended a higher risk of recurrence compared with T1 (T2/T1 hazard ratio [HR], 2.05 [P = 0.04]; T3/T1 HR, 2.31 [P = 0.07]). In addition, a location characteristic that increased the risk of tumor recurrence was tarsal involvement (AJCC T3 stage lesion; HR, 4.12; P = 0.007). Nasal location was associated with a decreased risk of tumor recurrence (HR, 0.41; P = 0.008). Pathologic characteristics significantly associated with tumor recurrence were the presence of positive margins (HR, 2.73; P = 0.008) and higher grade lesions (carcinoma in situ and squamous cell carcinoma versus dysplasia; HR, 2.55; P = 0.02). Treatment with adjuvant cryotherapy significantly decreased the risk of tumor recurrence (HR, 0.51; P = 0.03). In those patients with positive margins, the use of postoperative topical interferon therapy lowered the recurrence rate to a level similar to that of patients with negative margins. Certain patient and tumor factors are associated with a higher risk of OSSN recurrence after operative excision, such as tarsal tumor location and positive surgical margins. Postoperative adjuvant therapy should be considered in patients with high-risk OSSN characteristics." @default.
• W2133068052 created "2016-06-24" @default.
• W2133068052 creator A5006087398 @default.
• W2133068052 creator A5006131061 @default.
• W2133068052 creator A5038466176 @default.
• W2133068052 creator A5057215721 @default.
• W2133068052 creator A5077080693 @default.
• W2133068052 creator A5084526186 @default.
• W2133068052 creator A5086381937 @default.
• W2133068052 date "2012-10-01" @default.
• W2133068052 modified "2023-10-17" @default.
• W2133068052 title "Predictors of Ocular Surface Squamous Neoplasia Recurrence after Excisional Surgery" @default.
• W2133068052 cites W1605506735 @default.
• W2133068052 cites W173312179 @default.
• W2133068052 cites W1970804304 @default.
• W2133068052 cites W1972854825 @default.
• W2133068052 cites W1979799582 @default.
• W2133068052 cites W1985772737 @default.
• W2133068052 cites W1995177877 @default.
• W2133068052 cites W2009377629 @default.
• W2133068052 cites W2010281697 @default.
• W2133068052 cites W2031844429 @default.
• W2133068052 cites W2034287063 @default.
• W2133068052 cites W2036419372 @default.
• W2133068052 cites W2037481853 @default.
• W2133068052 cites W2041558443 @default.
• W2133068052 cites W2043586305 @default.
• W2133068052 cites W2048988823 @default.
• W2133068052 cites W2050037859 @default.
• W2133068052 cites W2064923395 @default.
• W2133068052 cites W2071171463 @default.
• W2133068052 cites W2078649043 @default.
• W2133068052 cites W2086541575 @default.
• W2133068052 cites W2088124612 @default.
• W2133068052 cites W2106563604 @default.
• W2133068052 cites W2107368875 @default.
• W2133068052 cites W2118454346 @default.
• W2133068052 cites W2143582995 @default.
• W2133068052 cites W2161042751 @default.
• W2133068052 cites W2166191901 @default.
• W2133068052 cites W2166262029 @default.
• W2133068052 cites W2168231114 @default.
• W2133068052 doi "https://doi.org/10.1016/j.ophtha.2012.04.022" @default.
• W2133068052 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3459154" @default.
• W2133068052 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22704832" @default.
• W2133068052 hasPublicationYear "2012" @default.
• W2133068052 type Work @default.
• W2133068052 sameAs 2133068052 @default.
• W2133068052 citedByCount "124" @default.
• W2133068052 countsByYear W21330680522013 @default.
• W2133068052 countsByYear W21330680522014 @default.
• W2133068052 countsByYear W21330680522015 @default.
• W2133068052 countsByYear W21330680522016 @default.
• W2133068052 countsByYear W21330680522017 @default.
• W2133068052 countsByYear W21330680522018 @default.
• W2133068052 countsByYear W21330680522019 @default.
• W2133068052 countsByYear W21330680522020 @default.
• W2133068052 countsByYear W21330680522021 @default.
• W2133068052 countsByYear W21330680522022 @default.
• W2133068052 countsByYear W21330680522023 @default.
• W2133068052 crossrefType "journal-article" @default.
• W2133068052 hasAuthorship W2133068052A5006087398 @default.
• W2133068052 hasAuthorship W2133068052A5006131061 @default.
• W2133068052 hasAuthorship W2133068052A5038466176 @default.
• W2133068052 hasAuthorship W2133068052A5057215721 @default.
• W2133068052 hasAuthorship W2133068052A5077080693 @default.
• W2133068052 hasAuthorship W2133068052A5084526186 @default.
• W2133068052 hasAuthorship W2133068052A5086381937 @default.
• W2133068052 hasBestOaLocation W21330680522 @default.
• W2133068052 hasConcept C121608353 @default.
• W2133068052 hasConcept C126322002 @default.
• W2133068052 hasConcept C141071460 @default.
• W2133068052 hasConcept C146357865 @default.
• W2133068052 hasConcept C151730666 @default.
• W2133068052 hasConcept C167135981 @default.
• W2133068052 hasConcept C207103383 @default.
• W2133068052 hasConcept C2775894508 @default.
• W2133068052 hasConcept C2775934546 @default.
• W2133068052 hasConcept C2777546739 @default.
• W2133068052 hasConcept C2777661416 @default.
• W2133068052 hasConcept C2780149145 @default.
• W2133068052 hasConcept C2781156865 @default.
• W2133068052 hasConcept C2991678472 @default.
• W2133068052 hasConcept C44249647 @default.
• W2133068052 hasConcept C71924100 @default.
• W2133068052 hasConcept C86803240 @default.
• W2133068052 hasConceptScore W2133068052C121608353 @default.
• W2133068052 hasConceptScore W2133068052C126322002 @default.
• W2133068052 hasConceptScore W2133068052C141071460 @default.
• W2133068052 hasConceptScore W2133068052C146357865 @default.
• W2133068052 hasConceptScore W2133068052C151730666 @default.
• W2133068052 hasConceptScore W2133068052C167135981 @default.
• W2133068052 hasConceptScore W2133068052C207103383 @default.
• W2133068052 hasConceptScore W2133068052C2775894508 @default.
• W2133068052 hasConceptScore W2133068052C2775934546 @default.
• W2133068052 hasConceptScore W2133068052C2777546739 @default.
• W2133068052 hasConceptScore W2133068052C2777661416 @default.
• W2133068052 hasConceptScore W2133068052C2780149145 @default.

• next